Antibodies AAV Adult Antisynthétase IMNM Male Amyotrophic lateral sclerosis Anticorps spécifique des myosites Machine learning Biopsy COVID-19 Mass cytometry Anti-interleukin-6 AAV vectors Myositis Inflammation Adverse drug reactions Acid-alpha-glucosidase Cardio-oncology Bioelectrical impedance analysis Aged Multidisciplinarity Fabry disease Middle Aged Case reports Animals Adeno-associated vector Aldosterone AAV vector Polymyositis Acute Kidney Injury/epidemiology/etiology Assisted communication devices B-lymphocyte Cytokines Biomarkers Aldostérone Myopathy Dermatomyositis Muscle Analyses multidimensionnelles Adolescence Anti-MDA5 autoantibodies Interstitial lung disease Anti-agalsidase antibodies Myositis and muscle disease Systems biology B cell homeostasis Antisynthetase Dependovirus/genetics/immunology Prognosis IBM Biomarker Pharmacology Anti-drug antibodies Data integration Anti-IgE IgG Inborn errors of metabolism Active Biomarqueurs AAV humoral immunity Skeletal muscle Arthritis Female Immune checkpoint inhibitors Autoantibody Cancer Antibody responses Amyotrophy AAV antibody Inclusion body myositis Anti‐mitochondrial antibodies Adeno-associated virus vector Outcome measures Immunotherapy Humans Autoantibodies Anti-Mi2 Lysosomal storage diseases Anti-synthetase syndrome Inflammatory myopathy Antiphospholipid syndrome Idiopathic inflammatory myopathies Auto-antibodies DM Autoimmune diseases Adeno-associated virus Anticorps anti-agalsidase Gene therapy Auto‐antibodies Autoimmunity Antisynthetase syndrome Auto-immunité Interferon Adjudication Deep immune profiling Abnormal movement Myocarditis Sphingosine-1-phosphate Anémie hémolytique Agalsidase